;PMID: 1651847
;source_file_1935.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..225] = [t:44..225]
;2)section:[e:229..269] = [t:229..269]
;3)section:[e:273..446] = [t:273..446]
;4)sentence:[e:450..566] = [t:450..566]
;5)sentence:[e:567..714] = [t:567..714]
;6)sentence:[e:715..815] = [t:715..815]
;7)sentence:[e:816..918] = [t:816..918]
;8)sentence:[e:920..1057] = [t:920..1057]
;9)sentence:[e:1058..1368] = [t:1058..1368]
;10)sentence:[e:1369..1563] = [t:1369..1563]
;11)sentence:[e:1564..1721] = [t:1564..1721]
;12)sentence:[e:1722..1874] = [t:1722..1874]
;13)sentence:[e:1875..2050] = [t:1875..2050]
;14)sentence:[e:2051..2180] = [t:2051..2180]
;15)section:[e:2184..2228] = [t:2184..2228]

;section 0 Span:0..38
;Endocrinology. 1991 Sep;129(3):1333-9.
(SEC
  (FRAG (RB:[0..13] Endocrinology) (JJ:[13..14] .) (CD:[15..19] 1991)
        (CC:[20..28] Sep;129-LRB-) (CD:[28..29] 3) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..35] 1333) (::[35..36] -) (CD:[36..38] 9.)))

;sentence 1 Span:44..225
;Prostaglandin E2 is a positive regulator of adrenocorticotropin receptors, 3 
;beta-hydroxysteroid dehydrogenase, and 17 alpha-hydroxylase expression in
;bovine  adrenocortical cells.
;[44..60]:substance:"Prostaglandin E2"
;[75..84]:substance:"regulator"
;[88..117]:substance:"adrenocorticotropin receptors"
;[119..155]:substance:"3  beta-hydroxysteroid dehydrogenase"
;[161..181]:cyp450:"17 alpha-hydroxylase"
(SENT
  (S-HLN
    (NP-SBJ (NN:[44..57] Prostaglandin) (NN:[58..60] E2))
    (VP (VBZ:[61..63] is)
      (NP-PRD
        (NP (DT:[64..65] a) (JJ:[66..74] positive) (NN:[75..84] regulator))
        (PP (IN:[85..87] of)
          (NP
            (NP (NN:[88..107] adrenocorticotropin) (NNS:[108..117] receptors))
            (,:[117..118] ,)
            (NP (CD:[119..120] 3) (NN:[122..141] beta-hydroxysteroid)
                (NN:[142..155] dehydrogenase))
            (,:[155..156] ,) (CC:[157..160] and)
            (NP
              (NML (CD:[161..163] 17) (NN:[164..181] alpha-hydroxylase))
              (NN:[182..192] expression)))))
      (PP-LOC (IN:[193..195] in)
        (NP (JJ:[196..202] bovine) (JJ:[204..218] adrenocortical)
            (NNS:[219..224] cells))))
    (.:[224..225] .)))

;section 2 Span:229..269
;Rainey WE, Naville D, Cline N, Mason JI.
(SEC
  (FRAG (NNP:[229..235] Rainey) (NNP:[236..238] WE) (,:[238..239] ,)
        (NNP:[240..247] Naville) (NNP:[248..249] D) (,:[249..250] ,)
        (NNP:[251..256] Cline) (NNP:[257..258] N) (,:[258..259] ,)
        (NNP:[260..265] Mason) (NNP:[266..269] JI.)))

;section 3 Span:273..446
;Cecil H. & Ida Green Center for Reproductive Biology Sciences, Department of 
;Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 
;Dallas 75235-9051.
(SEC
  (FRAG (NNP:[273..278] Cecil) (NNP:[279..281] H.) (CC:[282..283] &)
        (NNP:[284..287] Ida) (NNP:[288..293] Green) (NNP:[294..300] Center)
        (IN:[301..304] for) (NNP:[305..317] Reproductive)
        (NNP:[318..325] Biology) (NNP:[326..334] Sciences) (,:[334..335] ,)
        (NNP:[336..346] Department) (IN:[347..349] of)
        (NNP:[351..361] Obstetrics) (CC:[362..365] and)
        (NNP:[366..376] Gynecology) (,:[376..377] ,) (NNP:[378..388] University)
        (IN:[389..391] of) (NNP:[392..397] Texas) (NNP:[398..410] Southwestern)
        (NNP:[411..418] Medical) (NNP:[419..425] Center) (,:[425..426] ,)
        (NNP:[428..434] Dallas) (CD:[435..440] 75235) (HYPH:[440..441] -)
        (CD:[441..445] 9051) (.:[445..446] .)))

;sentence 4 Span:450..566
;The maintenance of optimal steroidogenesis in adrenocortical cells primarily 
;depends on the chronic action of cAMP.
;[561..565]:substance:"cAMP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[450..453] The) (NN:[454..465] maintenance))
      (PP (IN:[466..468] of)
        (NP (JJ:[469..476] optimal) (NN:[477..492] steroidogenesis)))
      (PP-LOC (IN:[493..495] in)
        (NP (JJ:[496..510] adrenocortical) (NNS:[511..516] cells))))
    (ADVP (RB:[517..526] primarily))
    (VP (VBZ:[528..535] depends)
      (PP-CLR (IN:[536..538] on)
        (NP
          (NP (DT:[539..542] the) (JJ:[543..550] chronic) (NN:[551..557] action))
          (PP (IN:[558..560] of)
            (NP (NN:[561..565] cAMP))))))
    (.:[565..566] .)))

;sentence 5 Span:567..714
;Herein we examine the effects of  prostaglandin E2 (PGE2) on the
;differentiated functions of bovine adrenocortical  (BAC) cells in primary
;culture.
;[601..617]:substance:"prostaglandin E2"
;[619..623]:substance:"PGE2"
(SENT
  (S
    (ADVP (RB:[567..573] Herein))
    (NP-SBJ (PRP:[574..576] we))
    (VP (VBP:[577..584] examine)
      (NP
        (NP (DT:[585..588] the) (NNS:[589..596] effects))
        (PP (IN:[597..599] of)
          (NP
            (NP (NN:[601..614] prostaglandin) (NN:[615..617] E2))
            (NP (-LRB-:[618..619] -LRB-) (NN:[619..623] PGE2)
                (-RRB-:[623..624] -RRB-))))
        (PP (IN:[625..627] on)
          (NP
            (NP (DT:[628..631] the) (VBN:[632..646] differentiated)
                (NNS:[647..656] functions))
            (PP (IN:[657..659] of)
              (NP
                (NML
                  (NML (JJ:[660..666] bovine) (JJ:[667..681] adrenocortical))
                  (NP (-LRB-:[683..684] -LRB-) (NN:[684..687] BAC)
                      (-RRB-:[687..688] -RRB-)))
                (NNS:[689..694] cells))))))
      (PP-LOC (IN:[695..697] in)
        (NP (JJ:[698..705] primary) (NN:[706..713] culture))))
    (.:[713..714] .)))

;sentence 6 Span:715..815
;PGE2 (10 microM) treatment for 3 h stimulated  steroidogenesis and cAMP
;production by over 100-fold.
;[715..719]:substance:"PGE2"
;[721..723]:quantitative-value:"10"
;[724..730]:quantitative-units:"microM"
;[746..747]:quantitative-value:"3"
;[748..749]:quantitative-units:"h"
;[782..786]:substance:"cAMP"
;[806..814]:quantitative-value:"100-fold"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[715..719] PGE2)
        (PRN (-LRB-:[720..721] -LRB-)
          (NP (CD:[721..723] 10) (NN:[724..730] microM))
          (-RRB-:[730..731] -RRB-))
        (NN:[732..741] treatment))
      (PP-TMP (IN:[742..745] for)
        (NP (CD:[746..747] 3) (NN:[748..749] h))))
    (VP (VBD:[750..760] stimulated)
      (NP
        (NP (NN:[762..777] steroidogenesis))
        (CC:[778..781] and)
        (NP (NN:[782..786] cAMP) (NN:[787..797] production)))
      (PP-EXT (IN:[798..800] by)
        (ADVP
          (QP (IN:[801..805] over)
             (CD:[806..809] 100) (HYPH:[809..810] -) (RB:[810..814] fold)))))
    (.:[814..815] .)))

;sentence 7 Span:816..918
;In addition, the cAMP  antagonist Rp-cAMP (1 mM) inhibited PGE2 stimulation
;of steroidogenesis by 60%.
;[833..837]:substance:"cAMP"
;[839..849]:substance:"antagonist"
;[850..857]:substance:"Rp-cAMP"
;[859..860]:quantitative-value:"1"
;[861..863]:quantitative-units:"mM"
;[875..879]:substance:"PGE2"
;[914..917]:quantitative-value:"60%"
(SENT
  (S
    (PP (IN:[816..818] In)
      (NP (NN:[819..827] addition)))
    (,:[827..828] ,)
    (NP-SBJ
      (NP (DT:[829..832] the) (NN:[833..837] cAMP) (NN:[839..849] antagonist))
      (NP (NN:[850..857] Rp-cAMP))
      (PRN (-LRB-:[858..859] -LRB-)
        (NP (CD:[859..860] 1) (NN:[861..863] mM))
        (-RRB-:[863..864] -RRB-)))
    (VP (VBD:[865..874] inhibited)
      (NP
        (NP (NN:[875..879] PGE2) (NN:[880..891] stimulation))
        (PP (IN:[892..894] of)
          (NP (NN:[895..910] steroidogenesis))))
      (PP-EXT (IN:[911..913] by)
        (NP (CD:[914..916] 60) (NN:[916..917] %))))
    (.:[917..918] .)))

;sentence 8 Span:920..1057
;This observation suggests that the cAMP second messenger system is
;responsible  for much of the PGE2-activated steroid hormone synthesis.
;[955..959]:substance:"cAMP"
;[1016..1020]:substance:"PGE2"
;[1031..1046]:substance:"steroid hormone"
(SENT
  (S
    (NP-SBJ (DT:[920..924] This) (NN:[925..936] observation))
    (VP (VBZ:[937..945] suggests)
      (SBAR (IN:[946..950] that)
        (S
          (NP-SBJ (DT:[951..954] the) (NN:[955..959] cAMP)
            (NML (JJ:[960..966] second) (NN:[967..976] messenger))
            (NN:[977..983] system))
          (VP (VBZ:[984..986] is)
            (ADJP-PRD (JJ:[987..998] responsible)
              (PP (IN:[1000..1003] for)
                (NP
                  (NP (JJ:[1004..1008] much))
                  (PP (IN:[1009..1011] of)
                    (NP (DT:[1012..1015] the)
                      (ADJP (NN:[1016..1020] PGE2) (HYPH:[1020..1021] -)
                            (VBN:[1021..1030] activated))
                      (NML (JJ:[1031..1038] steroid) (NN:[1039..1046] hormone))
                      (NN:[1047..1056] synthesis))))))))))
    (.:[1056..1057] .)))

;sentence 9 Span:1058..1368
;Chronic treatment of  BAC cells with PGE2 caused induction of 3
;beta-hydroxysteroid dehydrogenase and  steroid 17 alpha-hydroxylase
;cytochrome P-450 expression as determined by the  examination of enzyme
;activity, enzyme levels by immunoblotting, and specific  messenger RNA (mRNA)
;levels by Northern analysis.
;[1095..1099]:substance:"PGE2"
;[1122..1155]:substance:"beta-hydroxysteroid dehydrogenase"
;[1161..1206]:cyp450:"steroid 17 alpha-hydroxylase cytochrome P-450"
;[1255..1261]:substance:"enzyme"
;[1272..1278]:substance:"enzyme"
;[1319..1332]:substance:"messenger RNA"
;[1334..1338]:substance:"mRNA"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1058..1065] Chronic) (NN:[1066..1075] treatment))
      (PP (IN:[1076..1078] of)
        (NP (NN:[1080..1083] BAC) (NNS:[1084..1089] cells)))
      (PP (IN:[1090..1094] with)
        (NP (NN:[1095..1099] PGE2))))
    (VP (VBD:[1100..1106] caused)
      (NP
        (NP (NN:[1107..1116] induction))
        (PP (IN:[1117..1119] of)
          (NP
            (NP
              (NML (CD:[1120..1121] 3)
                 (NN:[1122..1141] beta-hydroxysteroid)
                 (NN:[1142..1155] dehydrogenase))
              (NML-2 (-NONE-:[1155..1155] *P*)))
            (CC:[1156..1159] and)
            (NP
              (NML (JJ:[1161..1168] steroid) (CD:[1169..1171] 17)
                   (NN:[1172..1189] alpha-hydroxylase))
              (NML-2
                (NML (NN:[1190..1200] cytochrome) (NN:[1201..1206] P-450))
                (NN:[1207..1217] expression))))))
      (SBAR-ADV (IN:[1218..1220] as)
        (S
          (NP-SBJ-1 (-NONE-:[1220..1220] *))
          (VP (VBN:[1221..1231] determined)
            (NP-1 (-NONE-:[1231..1231] *))
            (PP (IN:[1232..1234] by)
              (NP-LGS
                (NP (DT:[1235..1238] the) (NN:[1240..1251] examination))
                (PP (IN:[1252..1254] of)
                  (NP
                    (NP (NN:[1255..1261] enzyme) (NN:[1262..1270] activity))
                    (,:[1270..1271] ,)
                    (NP
                      (NP (NN:[1272..1278] enzyme) (NNS:[1279..1285] levels))
                      (PP (IN:[1286..1288] by)
                        (NP (NN:[1289..1303] immunoblotting))))
                    (,:[1303..1304] ,) (CC:[1305..1308] and)
                    (NP
                      (NP (JJ:[1309..1317] specific)
                        (NML
                          (NML (NN:[1319..1328] messenger) (NN:[1329..1332] RNA))
                          (NP (-LRB-:[1333..1334] -LRB-) (NN:[1334..1338] mRNA)
                              (-RRB-:[1338..1339] -RRB-)))
                        (NNS:[1340..1346] levels))
                      (PP (IN:[1347..1349] by)
                        (NP (JJ:[1350..1358] Northern)
                            (NN:[1359..1367] analysis))))))))))))
    (.:[1367..1368] .)))

;sentence 10 Span:1369..1563
;The positive effects of PGE2  on expression of 3 beta-hydroxysteroid
;dehydrogenase and 17 alpha-hydroxylase  cytochrome P-450 were similar to the
;effects seen after ACTH treatment of BAC  cells.
;[1393..1397]:substance:"PGE2"
;[1416..1451]:substance:"3 beta-hydroxysteroid dehydrogenase"
;[1456..1494]:cyp450:"17 alpha-hydroxylase  cytochrome P-450"
;[1534..1538]:substance:"ACTH"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1369..1372] The) (JJ:[1373..1381] positive)
          (NNS:[1382..1389] effects))
      (PP (IN:[1390..1392] of)
        (NP (NN:[1393..1397] PGE2)))
      (PP (IN:[1399..1401] on)
        (NP
          (NP (NN:[1402..1412] expression))
          (PP (IN:[1413..1415] of)
            (NP
              (NP
                (NML (CD:[1416..1417] 3) (NN:[1418..1437] beta-hydroxysteroid)
                     (NN:[1438..1451] dehydrogenase))
                (NML-1 (-NONE-:[1451..1451] *P*)))
              (CC:[1452..1455] and)
              (NP
                (NML (CD:[1456..1458] 17) (NN:[1459..1476] alpha-hydroxylase))
                (NML-1 (NN:[1478..1488] cytochrome) (NN:[1489..1494] P-450))))))))
    (VP (VBD:[1495..1499] were)
      (ADJP-PRD (JJ:[1500..1507] similar)
        (PP (TO:[1508..1510] to)
          (NP
            (NP (DT:[1511..1514] the) (NNS:[1515..1522] effects))
            (VP (VBN:[1523..1527] seen)
              (PP-TMP (IN:[1528..1533] after)
                (NP
                  (NP (NN:[1534..1538] ACTH) (NN:[1539..1548] treatment))
                  (PP (IN:[1549..1551] of)
                    (NP (NN:[1552..1555] BAC) (NNS:[1557..1562] cells))))))))))
    (.:[1562..1563] .)))

;sentence 11 Span:1564..1721
;In addition, treatment of BAC cells with PGE2 for 3 days caused a 3-fold 
;induction of ACTH receptors as determined by increased cell binding of 
;[125I]ACTH.
;[1605..1609]:substance:"PGE2"
;[1614..1615]:quantitative-value:"3"
;[1616..1620]:quantitative-units:"days"
;[1630..1636]:quantitative-value:"3-fold"
;[1651..1665]:substance:"ACTH receptors"
;[1710..1720]:substance:"[125I]ACTH"
(SENT
  (S
    (PP (IN:[1564..1566] In)
      (NP (NN:[1567..1575] addition)))
    (,:[1575..1576] ,)
    (NP-SBJ
      (NP (NN:[1577..1586] treatment))
      (PP (IN:[1587..1589] of)
        (NP (NN:[1590..1593] BAC) (NNS:[1594..1599] cells)))
      (PP (IN:[1600..1604] with)
        (NP (NN:[1605..1609] PGE2)))
      (PP-TMP (IN:[1610..1613] for)
        (NP (CD:[1614..1615] 3) (NNS:[1616..1620] days))))
    (VP (VBD:[1621..1627] caused)
      (NP
        (NP (DT:[1628..1629] a)
          (QP (CD:[1630..1631] 3) (HYPH:[1631..1632] -) (JJ:[1632..1636] fold))
          (NN:[1638..1647] induction))
        (PP (IN:[1648..1650] of)
          (NP (NN:[1651..1655] ACTH) (NNS:[1656..1665] receptors))))
      (SBAR-ADV (IN:[1666..1668] as)
        (S
          (NP-SBJ-1 (-NONE-:[1668..1668] *))
          (VP (VBN:[1669..1679] determined)
            (NP-1 (-NONE-:[1679..1679] *))
            (PP (IN:[1680..1682] by)
              (NP-LGS
                (NP (VBN:[1683..1692] increased) (NN:[1693..1697] cell)
                    (NN:[1698..1705] binding))
                (PP (IN:[1706..1708] of)
                  (NP (NN:[1710..1720] -LSB-125I-RSB-ACTH)))))))))
    (.:[1720..1721] .)))

;sentence 12 Span:1722..1874
;Finally, we determined that BAC cells produced PGE2 and that the  level of
;synthesis increased 10-fold after treatment with the hormone  angiotensin
;II.
;[1769..1773]:substance:"PGE2"
;[1817..1824]:quantitative-value:"10-fold"
;[1850..1857]:substance:"hormone"
;[1859..1873]:substance:"angiotensin II"
(SENT
  (S
    (ADVP (RB:[1722..1729] Finally))
    (,:[1729..1730] ,)
    (NP-SBJ (PRP:[1731..1733] we))
    (VP (VBD:[1734..1744] determined)
      (SBAR
        (SBAR (IN:[1745..1749] that)
          (S
            (NP-SBJ (NN:[1750..1753] BAC) (NNS:[1754..1759] cells))
            (VP (VBD:[1760..1768] produced)
              (NP (NN:[1769..1773] PGE2)))))
        (CC:[1774..1777] and)
        (SBAR (IN:[1778..1782] that)
          (S
            (NP-SBJ
              (NP (DT:[1783..1786] the) (NN:[1788..1793] level))
              (PP (IN:[1794..1796] of)
                (NP (NN:[1797..1806] synthesis))))
            (VP (VBD:[1807..1816] increased)
              (ADVP-EXT
                (QP (CD:[1817..1819] 10) (HYPH:[1819..1820] -)
                    (RB:[1820..1824] fold)))
              (PP-TMP (IN:[1825..1830] after)
                (NP
                  (NP (NN:[1831..1840] treatment))
                  (PP (IN:[1841..1845] with)
                    (NP
                      (NP (DT:[1846..1849] the) (NN:[1850..1857] hormone))
                      (NP (NN:[1859..1870] angiotensin) (CD:[1871..1873] II)))))))))))
    (.:[1873..1874] .)))

;sentence 13 Span:1875..2050
;Taken together these data indicate that PGE2 is a positive  regulator of BAC
;cell differentiation acting on ACTH receptors, steroid  metabolizing enzymes,
;and steroidogenesis.
;[1915..1919]:substance:"PGE2"
;[1935..1944]:substance:"regulator"
;[1983..1997]:substance:"ACTH receptors"
;[1999..2028]:substance:"steroid  metabolizing enzymes"
(SENT
  (S
    (S-ADV
      (NP-SBJ-1 (-NONE-:[1875..1875] *))
      (VP (VBN:[1875..1880] Taken)
        (NP-1 (-NONE-:[1880..1880] *))
        (ADVP (RB:[1881..1889] together))))
    (NP-SBJ (DT:[1890..1895] these) (NNS:[1896..1900] data))
    (VP (VBP:[1901..1909] indicate)
      (SBAR (IN:[1910..1914] that)
        (S
          (NP-SBJ (NN:[1915..1919] PGE2))
          (VP (VBZ:[1920..1922] is)
            (NP-PRD
              (NP
                (NP (DT:[1923..1924] a) (JJ:[1925..1933] positive)
                    (NN:[1935..1944] regulator))
                (PP (IN:[1945..1947] of)
                  (NP (NN:[1948..1951] BAC) (NN:[1952..1956] cell)
                      (NN:[1957..1972] differentiation))))
              (VP (VBG:[1973..1979] acting)
                (PP-CLR (IN:[1980..1982] on)
                  (NP
                    (NP (NN:[1983..1987] ACTH) (NNS:[1988..1997] receptors))
                    (,:[1997..1998] ,)
                    (NP
                      (ADJP (NN:[1999..2006] steroid)
                            (VBG:[2008..2020] metabolizing))
                      (NNS:[2021..2028] enzymes))
                    (,:[2028..2029] ,) (CC:[2030..2033] and)
                    (NP (NN:[2034..2049] steroidogenesis))))))))))
    (.:[2049..2050] .)))

;sentence 14 Span:2051..2180
;The ability of BAC cells to produce  PGE2 leaves open the possibility for
;paracrine and autocrine regulation within  the adrenal.
;[2088..2092]:substance:"PGE2"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2051..2054] The) (NN:[2055..2062] ability)
        (S-2 (-NONE-:[2062..2062] *ICH*)))
      (PP (IN:[2063..2065] of)
        (NP (NN:[2066..2069] BAC) (NNS:[2070..2075] cells)))
      (S-2
        (NP-SBJ (-NONE-:[2075..2075] *))
        (VP (TO:[2076..2078] to)
          (VP (VB:[2079..2086] produce)
            (NP (NN:[2088..2092] PGE2))))))
    (VP (VBZ:[2093..2099] leaves)
      (S-CLR
        (NP-SBJ (-NONE-:[2099..2099] *))
        (ADJP-PRD (RP:[2100..2104] open)))
      (NP
        (NP (DT:[2105..2108] the) (NN:[2109..2120] possibility))
        (PP (IN:[2121..2124] for)
          (NP
            (NP (JJ:[2125..2134] paracrine)
              (NML-1 (-NONE-:[2134..2134] *P*)))
            (CC:[2135..2138] and)
            (NP (JJ:[2139..2148] autocrine)
              (NML-1 (NN:[2149..2159] regulation))))))
      (PP-LOC (IN:[2160..2166] within)
        (NP (DT:[2168..2171] the) (JJ:[2172..2179] adrenal))))
    (.:[2179..2180] .)))

;section 15 Span:2184..2228
;PMID: 1651847 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2184..2188] PMID) (::[2188..2189] :) (CD:[2190..2197] 1651847)
        (NN:[2198..2199] -LSB-) (NNP:[2199..2205] PubMed) (::[2206..2207] -)
        (NN:[2208..2215] indexed) (IN:[2216..2219] for)
        (NNP:[2220..2228] MEDLINE-RSB-)))
